Report from the CVOT Summit 2020: new cardiovascular and renal outcomes

Oliver Schnell; Xavier Cos; Francesco Cosentino; Thomas Forst; Francesco Giorgino; Hiddo J. L. Heersprink; Mikhail Kosiborod; Christoph Wanner; Eberhard Standl

doi:10.1186/s12933-021-01254-1

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes

Oliver Schnell^*, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J. L. Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

8 Citations (Scopus)

72 Downloads (Pure)

Abstract

The 6th Cardiovascular Outcome Trial (CVOT) Summit "Cardiovascular and Renal Outcomes 2020" was the first to be held virtually on October 29-30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA- CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.

The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18-19, 2021 (http://www.cvot.org).

Original language	English
Article number	75
Number of pages	12
Journal	Cardiovascular Diabetology
Volume	20
Issue number	1
DOIs	https://doi.org/10.1186/s12933-021-01254-1
Publication status	Published - 31-Mar-2021

Keywords

Diabetes
Cardiovascular disease
Heart failure
Chronic kidney disease
Obesity
VERTIS-CV
EMPEROR-Reduced
DAPA-CKD
FIDELIO-DKD
SGLT2i inhibitor
GLP-1 receptor agonist
Mineralocorticoid receptor antagonist

Access to Document

10.1186/s12933-021-01254-1Licence: CC BY

Report from the CVOT Summit 2020: new cardiovascular and renal outcomesFinal publisher's version, 1.06 MBLicence: CC BY

Handle.net

Persistent link

Cite this

@article{14cb434759e14c1abd5f40785c672c4f,

title = "Report from the CVOT Summit 2020: new cardiovascular and renal outcomes",

abstract = "The 6th Cardiovascular Outcome Trial (CVOT) Summit {"}Cardiovascular and Renal Outcomes 2020{"} was the first to be held virtually on October 29-30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA- CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18-19, 2021 (http://www.cvot.org).",

keywords = "Diabetes, Cardiovascular disease, Heart failure, Chronic kidney disease, Obesity, VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, FIDELIO-DKD, SGLT2i inhibitor, GLP-1 receptor agonist, Mineralocorticoid receptor antagonist",

author = "Oliver Schnell and Xavier Cos and Francesco Cosentino and Thomas Forst and Francesco Giorgino and Heersprink, {Hiddo J. L.} and Mikhail Kosiborod and Christoph Wanner and Eberhard Standl",

year = "2021",

month = mar,

day = "31",

doi = "10.1186/s12933-021-01254-1",

language = "English",

volume = "20",

journal = "Cardiovascular Diabetology",

issn = "1475-2840",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Report from the CVOT Summit 2020

T2 - new cardiovascular and renal outcomes

AU - Schnell, Oliver

AU - Cos, Xavier

AU - Cosentino, Francesco

AU - Forst, Thomas

AU - Giorgino, Francesco

AU - Heersprink, Hiddo J. L.

AU - Kosiborod, Mikhail

AU - Wanner, Christoph

AU - Standl, Eberhard

PY - 2021/3/31

Y1 - 2021/3/31

N2 - The 6th Cardiovascular Outcome Trial (CVOT) Summit "Cardiovascular and Renal Outcomes 2020" was the first to be held virtually on October 29-30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA- CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18-19, 2021 (http://www.cvot.org).

AB - The 6th Cardiovascular Outcome Trial (CVOT) Summit "Cardiovascular and Renal Outcomes 2020" was the first to be held virtually on October 29-30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA- CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18-19, 2021 (http://www.cvot.org).

KW - Diabetes

KW - Cardiovascular disease

KW - Heart failure

KW - Chronic kidney disease

KW - Obesity

KW - VERTIS-CV

KW - EMPEROR-Reduced

KW - DAPA-CKD

KW - FIDELIO-DKD

KW - SGLT2i inhibitor

KW - GLP-1 receptor agonist

KW - Mineralocorticoid receptor antagonist

U2 - 10.1186/s12933-021-01254-1

DO - 10.1186/s12933-021-01254-1

M3 - Editorial

SN - 1475-2840

VL - 20

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

IS - 1

M1 - 75

ER -

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this